PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Pumping the brakes on autoimmune disease

New study describes the science behind an autoimmune disease treatment in a Phase 2 clinical trial

Pumping the brakes on autoimmune disease
2023-06-05
(Press-News.org) LA JOLLA, CALIF. – June 5, 2023 – Researchers at Sanford Burnham Prebys, collaborating with scientists from Eli Lilly and Company, have revealed the structure and function of a drug called LY3361237, which can reduce the harmful activity of the immune system to help treat autoimmune diseases. Their work laid the foundation for a new treatment that’s currently in a Phase 2 clinical trial for lupus, an autoimmune disease affecting multiple organs in the body. The study is published in Structure, a Cell Press journal.

The findings could also help scientists discover more drugs that target the immune system, a rapidly growing area of biomedical research.

“It’s miraculous that we can change the activity of the immune system with drugs, but we’re still at an incredibly early stage in terms of figuring out how this works,” says Professor Carl Ware, Ph.D. “The drug we describe in this study is an antibody that has shown promise in initial clinical trials, but understanding how it works on a molecular level will help scientists discover even more ways to modify the immune system to treat autoimmune diseases.”

Autoimmune diseases occur when the immune system attacks the body. There are more than 80 known autoimmune diseases, and researchers estimate that about 5–10% of the population is affected by these diseases. Some well-known examples include rheumatoid arthritis, psoriasis and lupus.

“Immunological disorders are a major unmet medical need,” says Ware. “Some can be managed effectively, but most of these diseases have limited treatment options, so many people just have to learn to live with the symptoms.”

The newly published study is the culmination of a long-standing collaboration between Sanford Burnham Prebys and Eli Lilly and Company. Their goal was to find a way to temper the activity of the immune system in autoimmune diseases. They were able to discover that LY3361237 can rebalance the immune system to prevent it from attacking the body.

The drug works by activating a chemical messenger in the immune system called BTLA, which is a major focus of Ware’s research. In healthy people, BTLA is an immune checkpoint—a brake for the immune system to stop it from continuing to fire once an infection is under control. However, in people with autoimmune diseases, this brake never engages, so the immune system doesn’t know when to slow down.

“LY3361237 is the first antibody drug that’s known to increase the activity of BTLA to inhibit the immune system, which means it has extraordinary potential as a therapy for autoimmune diseases,” says Ware.

The drug produced by Lilly entered a Phase 1 clinical trial in healthy subjects in 2018, and began recruiting patients with lupus for a Phase 2 trial in 2021. This trial will evaluate the efficacy and safety of the new treatment and is expected to be completed in two to four years.

In the meantime, the recently published study in Structure can provide a treasure trove of information for researchers studying the molecular biology of the immune system, which could help drive the discovery of more potential therapeutics for immunological diseases.

###

Additional authors on the study include Timothy C. Cheung, Paulina Delgado Cuenca, Jiawen Huang and Stacie Lim, Sanford Burnham Prebys; Shane Atwell, Lisa Bafetti, Karen Froning, Jörg Hendle, Michael Hickey, Carolyn Ho, Ricky Lieu, David Lippner, Victor Obungu, Lindsay Ward-Kavanagh, Kenneth Weichert and Andrew C. Vendel, Eli Lilly and Company.

The study was supported by SBP-Lilly Collaborative Research Agreement (RCA15-15).

The study’s DOI is 10.1016/j.str.2023.05.011

About Sanford Burnham Prebys

Sanford Burnham Prebys is an independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 45 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

END

[Attachments] See images for this press release:
Pumping the brakes on autoimmune disease Pumping the brakes on autoimmune disease 2

ELSE PRESS RELEASES FROM THIS DATE:

Scientists use machine learning to ‘see’ how the brain adapts to different environments

Scientists use machine learning to ‘see’ how the brain adapts to different environments
2023-06-05
FOR IMMEDIATE RELEASE Johns Hopkins scientists have developed a method involving artificial intelligence to visualize and track changes in the strength of synapses — the connection points through which nerve cells in the brain communicate — in live animals. The technique, described in Nature Methods, should lead, the scientists say, to a better understanding of how such connections in human brains change with learning, aging, injury and disease. “If you want to learn more about how an orchestra plays, you have to watch individual players over time, and this ...

Cancer discoveries could enhance immunotherapy, breast cancer care

Cancer discoveries could enhance immunotherapy, breast cancer care
2023-06-05
Two new discoveries from the Dudley lab at UVA Cancer Center highlight the different roles of blood vessels in solid tumors  – and the findings could help prevent breast cancer from spreading and enhance the effectiveness of one of the most important new cancer treatments in many years. In one new scientific paper, researcher Andrew C. Dudley, PhD, and his team report that the effectiveness of immunotherapy drugs called immune check blockade is enhanced when blood vessels are targeted in a specific way. (Immunotherapy enhances the power of the immune system to fight cancer and other diseases.) In another paper, published ...

Refining surge protector in crops could boost yields

Refining surge protector in crops could boost yields
2023-06-05
Awash in a rowed sea of its brethren, a corn leaf relegated to the lowest rung of its stem spends much of a June afternoon doused in shade cast by the higher-ups. Then a gust begins pushing, pulling and twisting the waxy wings in concert, cracking a window to the fireball roiling 93 million miles away. It’s a prime, precious opportunity for photosynthesis to transform the sunlight into food. Unfortunately, the photosynthetic equivalent of a surge protector — one evolved to help plants mitigate damage driven by sudden spikes of high-intensity light — is slow to reset after so much time in the shade. The gust dissipates, the moment ...

Moving towards a more inclusive approach to medicine

2023-06-05
Moving towards a more inclusive approach to medicine Release of pangenome representing wide diversity of individuals ushers in new understanding of human biology and disease The first human genome, which has served as the reference until now, was released approximately 20 years ago. It was a landmark accomplishment that had a huge impact on biomedical research and changed the way scientists study human biology. But it was based on just a few individuals and did not capture the full genetic diversity of the human population. An important step forward for both biology and biomedical research “Since ...

SwRI investigates accuracy of flow meters measuring hydrogen and natural gas blends

SwRI investigates accuracy of flow meters measuring hydrogen and natural gas blends
2023-06-05
SAN ANTONIO — June 5, 2023 —Southwest Research Institute is expanding its flow meter research in collaboration with NYSEARCH, a nonprofit research and development organization for the gas industry, to address the impact of introducing hydrogen and natural gas blends into the residential and commercial energy mix. In the second phase of the program, SwRI will expand its research in measuring the energy content of blended gas to determine the accuracy of current flow meter technology for monitoring usage in homes. Natural gas is widely used to power appliances and heat ...

Social media posts can be used to track individuals’ income and economic inequalities

2023-06-05
Researchers from Queen Mary University of London analysed 2.6 million posts on popular social media network Nextdoor and accurately predicted individuals’ income by solely examining the posts they’ve published. Striking differences in the content shared by people who live in wealthier versus poorer neighbourhoods has led researchers to believe that our general online posting activity, beyond Nextdoor, can reveal our socioeconomic status, making user profiling possible. Knowing users’ income could allow social media platforms to recommend income-based content, and advertisers and online shops can target people based on their ...

ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
2023-06-05
ABSTRACTS: 3121, 4504, LBA4619 CHICAGO ― Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations. The data are being presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Erdafitinib is an oral medication that blocks the activity of FGFR signaling proteins, which are important for a variety of normal cellular processes. However, FGFR genetic alterations can drive the development of many ...

Patchwork of mutations contributing to bipolar disorder

Patchwork of mutations contributing to bipolar disorder
2023-06-05
Bipolar disorder (BD) is a major psychiatric condition that afflicts about 1% of people. Symptoms of BD include sudden onset of depressive mood with loss of interest which alternates with a manic state of hyperactivity. The suffering of the patients and societal cost of this disorder requires the use of continued therapeutic management. Current medications—although vital for patients with BD—are not perfect solutions, given their potential side-effects and treatment resistance. This necessitates ...

Zap Energy charts roadmap for measuring fusion gain

Zap Energy charts roadmap for measuring fusion gain
2023-06-05
In the race to develop fusion energy, each unique approach requires its own specialized techniques to determine net energy gain, an equation balancing energy in and out that’s known by the letter Q. A new paper, published today in the journal Fusion Science and Technology, establishes the company’s method of measuring and calculating Q in Zap’s sheared-flow-stabilized Z-pinch fusion plasmas. The publication will be an important part of Zap demonstrating energy gain on the way to building a commercial fusion ...

Children with attention, behavior problems earn less money, have less education, poorer health as adults

2023-06-05
Children who struggle with attention and behavior problems tend to end up earning less money, finish fewer years of school and have poorer mental and physical health as adults, compared with children who don’t show early attention and behavior problems, according to research published by the American Psychological Association. Children who struggle with attention are particularly likely to have lower levels of educational attainment as adults, while those who struggle with impulsivity are more likely to end up in trouble with the law, the research found. “Our study found broad support ...

LAST 30 PRESS RELEASES:

Global cervical cancer vaccine roll-out shows it to be very effective in reducing cervical cancer and other HPV-related disease, but huge variations between countries in coverage

Negativity about vaccines surged on Twitter after COVID-19 jabs become available

Global measles cases almost double in a year

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen

Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in treating a common form of irritable bowel syndrome, pilot study finds

Experts developing immune-enhancing therapies to target tuberculosis

Making transfusion-transmitted malaria in Europe a thing of the past

Experts developing way to harness Nobel Prize winning CRISPR technology to deal with antimicrobial resistance (AMR)

CRISPR is promising to tackle antimicrobial resistance, but remember bacteria can fight back

Ancient Maya blessed their ballcourts

Curran named Fellow of SAE, ASME

Computer scientists unveil novel attacks on cybersecurity

Florida International University graduate student selected for inaugural IDEA2 public policy fellowship

Gene linked to epilepsy, autism decoded in new study

OHSU study finds big jump in addiction treatment at community health clinics

Location, location, location

Getting dynamic information from static snapshots

Food insecurity is significant among inhabitants of the region affected by the Belo Monte dam in Brazil

The Society of Thoracic Surgeons launches new valve surgery risk calculators

Component of keto diet plus immunotherapy may reduce prostate cancer

New circuit boards can be repeatedly recycled

Blood test finds knee osteoarthritis up to eight years before it appears on x-rays

April research news from the Ecological Society of America

Antimicrobial resistance crisis: “Antibiotics are not magic bullets”

Florida dolphin found with highly pathogenic avian flu: Report

Barcodes expand range of high-resolution sensor

DOE Under Secretary for Science and Innovation visits Jefferson Lab

Research expo highlights student and faculty creativity

Imaging technique shows new details of peptide structures

MD Anderson and RUSH unveil RUSH MD Anderson Cancer Center

[Press-News.org] Pumping the brakes on autoimmune disease
New study describes the science behind an autoimmune disease treatment in a Phase 2 clinical trial